Schneider, J. L., Lin, J. J. & Shaw, A. T. ALK-positive lung cancer: a moving target. Nat Cancer 4, 330–343 (2023). Article CAS PubMed PubMed Central Google Scholar Voena, C., Ambrogio, C., Iannelli, F. & Chiarle, R. ALK in cancer: from function to therapeutic targeting. Nat. Rev. Cancer 25, 359–378 (2025). Article CAS PubMed PubMed
Schneider, J. L., Lin, J. J. & Shaw, A. T. ALK-positive lung cancer: a moving target. Nat Cancer 4, 330–343 (2023).
Google Scholar
Voena, C., Ambrogio, C., Iannelli, F. & Chiarle, R. ALK in cancer: from function to therapeutic targeting. Nat. Rev. Cancer 25, 359–378 (2025).
Google Scholar
Shaw, A. T. et al. Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study. Ann. Oncol. https://doi.org/10.1016/j.annonc.2026.05.692 (2026).
Saifudeen, M. et al. Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing. Nat. Biotechnol. https://doi.org/10.1038/s41587-026-03090-8 (2026).
Yoda, S. et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 8, 714–729 (2018).
Google Scholar
Igawa, Y. et al. Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification. Lung Cancer 196, 107954 (2024).
Google Scholar
Lai, A. C. & Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101–114 (2017).
Google Scholar
Gao, Y. et al. Catalytic degraders effectively address kinase site mutations in EML4-ALK oncogenic fusions. J. Med. Chem. 66, 5524–5535 (2023).
Google Scholar
Kang, C. H. et al. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC). Biochem. Biophys. Res. Commun. 505, 542–547 (2018).
Google Scholar
Li, X. et al. A small-molecule degrader selectively inhibits the growth of ALK-rearranged lung cancer with ceritinib resistance. iScience 27, 109015 (2024).
Google Scholar
Ren, C. et al. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from alectinib. Eur. J. Med. Chem. 217, 113335 (2021).
Google Scholar
Sun, N. et al. Development of a brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. Eur. J. Med. Chem. 193, 112190 (2020).
Google Scholar
Yan, G. et al. Discovery of a PROTAC targeting ALK with in vivo activity. Eur. J. Med. Chem. 212, 113150 (2021).
Google Scholar
Zhang, C. et al. Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK). Eur. J. Med. Chem. 151, 304–314 (2018).
Google Scholar
La, D. S., Nasveschuk, C. G. & Gilbert, A. M. in 2025 Medicinal Chemistry Reviews Medicinal Chemistry Reviews (eds Rudolph, J. & Watkins, W.) 399–427 (ACS, 2025).
Kozicka, Z. & Thoma, N. H. Haven’t got a glue: protein surface variation for the design of molecular glue degraders. Cell Chem. Biol 28, 1032–1047 (2021).
Google Scholar
Vetma, V., O’Connor, S. & Ciulli, A. Development of PROTAC degrader drugs for cancer. Annual Rev. Cancer Biol. 9, 119–140 (2025).
Google Scholar
Agarwal, P., Reid, D. L. & Amiji, M. CNS delivery of targeted protein degraders. J. Control. Release 372, 661–673 (2024).
Google Scholar
Wager, T. T., Hou, X., Verhoest, P. R. & Villalobos, A. Central nervous system multiparameter optimization desirability: application in drug discovery. ACS Chem. Neurosci. 7, 767–775 (2016).
Google Scholar
La, D. et al. Anaplastic lymphoma kinase (ALK) degraders and uses thereof. US patent WO/2026/035999 (2026).
Drilon, A. et al. ROS1-dependent cancers—biology, diagnostics and therapeutics. Nat. Rev. Clin. Oncol. 18, 35–55 (2021).
Google Scholar
Camidge, D. R. Lorlatinib should not be considered as the preferred first-line option in patients with advanced ALK rearranged NSCLC. J. Thorac. Oncol. 16, 528–531 (2021).
Google Scholar
Liu, D. et al. Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann. Oncol. 31, 1207–1215 (2020).
Google Scholar
Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 535, 252–257 (2016).
Google Scholar
Nishiguchi, G. et al. Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines. Nat. Commun. 15, 482 (2024).
Google Scholar
Sakamoto, H. et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19, 679–690 (2011).
Google Scholar
Watson, E. R. et al. Molecular glue CELMoD compounds are regulators of cereblon conformation. Science 378, 549–553 (2022).
Google Scholar
Petzold, G., Fischer, E. S. & Thoma, N. H. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase. Nature 532, 127–130 (2016).
Google Scholar
Petzold, G. et al. Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition. Science 389, eadt6736 (2025).
Google Scholar
Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797 (2007).
Google Scholar
Shiba-Ishii, A. et al. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat. Cancer 3, 710–722 (2022).
Google Scholar
Highlights of Prescribing Information for Lorbrena https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf (2021).
Zou, H. Y. et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 28, 70–81 (2015).
Google Scholar
Taipale, M. et al. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat. Biotechnol. 31, 630–637 (2013).
Google Scholar
Pacheco, J. M. et al. Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J. Thorac. Oncol. 14, 691–700 (2019).
Google Scholar
Lin, J. J. et al. NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations. Cancer Discov. 14, 2367–2386 (2024).
Google Scholar
Poirson, J. et al. Proteome-scale discovery of protein degradation and stabilization effectors. Nature 628, 878–886 (2024).
Google Scholar
Reichermeier, K. M. et al. PIKES analysis reveals response to degraders and key regulatory mechanisms of the CRL4 network. Mol. Cell 77, 1092–1106 e1099 (2020).
Google Scholar
Orthofer, M. et al. Identification of ALK in thinness. Cell 181, 1246–1262 (2020).
Google Scholar
Matyskiela, M. E. et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat. Chem. Biol. 14, 981–987 (2018).
Google Scholar
Lin, J. J. et al. ALKOVE-1: efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC. J. Clin. Oncol. 44, 8503–8503 (2026).
Google Scholar
Dagogo-Jack, I. et al. MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin. Cancer Res. 26, 2535–2545 (2020).
Google Scholar
Eide, C. A. et al. Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy. Cancer Cell 42, 1486–1488 (2024).
Google Scholar
Nagasaka, M. et al. The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib. NPJ Precis. Oncol. https://doi.org/10.1038/s41698-026-01477-z (2026).
Bird, S. & Pawlyn, C. IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact. Blood 142, 131–140 (2023).
Google Scholar
Isozaki, H. et al. Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature 620, 393–401 (2023).
Google Scholar
Katayama, R. et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin. Cancer Res. 20, 5686–5696 (2014).
Google Scholar
de la Rosa-Trevin, J. M. et al. Scipion: A software framework toward integration, reproducibility and validation in 3D electron microscopy. J. Struct. Biol. 195, 93–99 (2016).
Google Scholar
Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519–530 (2012).
Google Scholar
Meng, E. C. et al. UCSF ChimeraX: tools for structure building and analysis. Protein Sci. 32, e4792 (2023).
Google Scholar
Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D 74, 519–530 (2018).
Google Scholar
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).
Google Scholar
Yamashita, K., Palmer, C. M., Burnley, T. & Murshudov, G. N. Cryo-EM single-particle structure refinement and map calculation using Servalcat. Acta Crystallogr. D 77, 1282–1291 (2021).
Google Scholar
Dallakyan, S. & Olson, A. J. Small-molecule library screening by docking with PyRx. Methods Mol. Biol. 1263, 243–250 (2015).
Google Scholar
MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics https://doi.org/10.1093/bioinformatics/btq054 (2010).
Yamazaki, S. et al. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1. J. Pharmacol. Exp. Ther. 351, 67–76 (2014).
Google Scholar
Check back often for more exciting news!
